Dexcom Q2 Revenue Jumps 13% to $1.31B, Operating Income Surges 50%
DXCM sits 49% above its 52-week low of $54.11.
Summary
Dexcom reported Q2 2026 revenue of $1.31 billion, up 13% year-over-year, with operating income surging 50% to $318 million. Gross margins expanded to 63.4%, and the company repurchased $600 million in stock.
Key Events · Earnings and Guidance · DXCM
-
Revenue Growth Accelerates
Q2 revenue reached $1.308 billion, a 13% increase year-over-year, driven by 11% U.S. growth and 19% international growth. The company added approximately 600,000 to 700,000 net new customers in 2025, fueling sensor volume growth.
-
Profitability Surges
GAAP operating income jumped 50% to $318.3 million, with operating margin expanding to 24% from 18% a year ago. Net income rose 39% to $249.1 million, or $0.64 per diluted share.
-
Gross Margin Expansion
Gross margin improved to 63.4% from 59.5%, driven by G7 15 Day benefits, improved manufacturing efficiencies, and higher production volumes, partially offset by higher inventory reserve charges related to G6 discontinuation.
-
Aggressive Share Repurchases
Dexcom repurchased 8.6 million shares for $600 million during the quarter under a new $1 billion buyback program authorized in May 2026. The company ended the quarter with $1.95 billion in cash and marketable securities.
Analysis · DXCM · Industrial Applications And Services
A standout quarter for Dexcom saw revenue growth accelerate to 13% year-over-year, fueled by robust U.S. and international demand for its G7 and Stelo CGM systems. Gross margin expanded sharply to 63.4%, reflecting manufacturing efficiencies and the benefits of the G7 15 Day sensor. Operating income surged 50%, demonstrating significant operating leverage. The balance sheet remains fortress-like with $1.95 billion in cash and no borrowings, while management deployed $600 million to repurchase 8.6 million shares under a new $1 billion buyback program. These results reinforce Dexcom's leadership in the rapidly growing CGM market and its ability to convert top-line growth into substantial profitability.
At the time of this filing, DXCM was trading at $80.39 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $28.8B. The 52-week trading range was $54.11 to $89.98. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.